NSE: ABBOTINDIA · BSE: 500488
ABBOTT INDIA LIMITED
A pharmaceuticals company operating in India and the local pharma arm of Abbott Laboratories. It is a pharma-only firm (no medical devices or diagnostics in its Indian operations) that reported Rs 6,929 crore in revenue from operations for FY26, up 8.1% from FY25. Manufacturing is concentrated at a single formulation plant in Goa, supported by 3,467 permanent employees. Recent launches included Extensior (semaglutide) for Type 2 diabetes and Ezybixy for chronic constipation, extending its branded pharma portfolio. Operating costs are spread across materials at 8.9% of revenue, employee costs at 9.7% and other operating expenses at 9.7%, with depreciation at 1.1%. EBITDA for FY26 was Rs 2,180 crore, translating to a 31.46% EBITDA margin, and profit after tax stood at Rs 1,552 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical products. Branded pharma distribution and formulation, asset-light with a single Indian manufacturing plant, subsidiary of Abbott Laboratories
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 |
| EBITDA (ex other income) | 1,088 | 1,206 | 1,453 | 1,695 | 1,892 |
| margin % | 22.1 | 22.5 | 24.8 | 26.4 | 27.3 |
| Owners' profit | 799 | 949 | 1,201 | 1,414 | 1,552 |
| EPS, as reported (₹) | 375.86 | 446.78 | 446.78 | 665.62 | 730.36 |
| ROE % · ROCE % | 28.3 · 36.4 | 29.8 · 38.5 | 32.5 · 42.3 | 33.4 · 42.1 | 32.5 · 41.9 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 948 | 893 | 1,213 | 1,012 | 1,319 |
| Capex | (44) | (34) | (48) | (53) | (41) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 |
| Profit before tax | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 |
| Net profit | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 |
| EPS (₹) | 154.36 | 168.76 | 169.78 | 172.72 | 172.17 | 195.42 | 176.92 | 185.85 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 36.1 | 30.8 | 95 of 158 | 40% |
| P/B | 11.8 | 3.1 | 149 of 163 | 9% |
| ROCE | 41.4 | 10.8 | 7 of 183 | 97% |
| ROE | 32.5 | 9.8 | 10 of 166 | 95% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 32.5 | 17.5 | 26 of 165 | 85% |
| Revenue growth | 6.5 | 16.3 | 107 of 161 | 34% |
| Profit growth | 7.6 | 30.9 | 103 of 158 | 35% |
| Market cap | 56079 | 806 | 14 of 181 | 93% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 26 Oct 2026 · Board meeting set for November 5 to approve Q2 and H1 results | results | low | — | — |
| 6 Oct 2026 · Routine dematerialization compliance certificate for Jul-Sep 2026 quarter | compliance | minimal | — | — |
| 2 Oct 2026 · Newspaper ad on special window for physical share dematerialization | compliance | minimal | — | — |
| 28 Sept 2026 · Trading window closure ahead of Q2 FY27 results | compliance | minimal | — | — |
| 7 Sept 2026 · Company Secretary Sangeeta Shetty resigns, effective Oct 28, 2026 | management changes | high | — | — |
| 13 Aug 2026 · Abbott India 82nd AGM: new Chairman appointed, total dividend of Rs 656 per share | board shareholder meetings | medium | — | — |
| 4 Aug 2026 · Board Meeting on Aug 12, 2026 to Consider Q1 FY27 Results | results | low | — | — |
| 4 Aug 2026 · Special Window Open for Physical Share Transfer and Demat | compliance | minimal | — | — |
| 20 Jul 2026 · Abbott India 82nd AGM on Aug 13, total dividend of Rs 656 per share announced | compliance | minimal | — | — |
| 20 Jul 2026 · Weblink for FY26 Annual Report shared with shareholders | compliance | minimal | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.